

Verona Pharma Plc (VRNA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/V35B12B461FEN.html>

Date: April 2021

Pages: 56

Price: US\$ 125.00 (Single User License)

ID: V35B12B461FEN

Abstracts

Verona Pharma Plc (VRNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Verona Pharma Plc (Verona Pharma) is a clinical-stage biopharmaceutical company that focuses on the development and marketing of therapies for the treatment of respiratory diseases. The company's lead investigating candidate, ensifentrine, a bronchodilator/anti-inflammatory agent intended for the treatment of chronic obstructive pulmonary disease (COPD) in Phase III clinical trials; additional formulations of ensifentrine for the treatment of COPD: a dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI); in Phase II clinical studies; and ensifentrine in several pre-clinical studies in patients with the novel corona virus (COVID-19). Verona Pharma is headquartered in London, the UK.

Verona Pharma Plc Key Recent Developments

Mar 01,2021: Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Feb 18,2021: Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Nov 23,2020: Verona Pharma secures up to \$30 million debt financing from Silicon Valley Bank

Oct 29,2020: Verona Pharma operational update and financial results for the three and

nine months ended September 30, 2020

Aug 14,2020: Verona Pharma operational update and financial results for the three and six months ended June 30, 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Verona Pharma Plc - Key Facts
Verona Pharma Plc - Key Employees
Verona Pharma Plc - Key Employee Biographies
Verona Pharma Plc - Major Products and Services
Verona Pharma Plc - History
Verona Pharma Plc - Company Statement
Verona Pharma Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Verona Pharma Plc - Business Description
R&D Overview
Verona Pharma Plc - Corporate Strategy
Verona Pharma Plc - SWOT Analysis
SWOT Analysis - Overview
Verona Pharma Plc - Strengths
Verona Pharma Plc - Weaknesses
Verona Pharma Plc - Opportunities
Verona Pharma Plc - Threats
Verona Pharma Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES

Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Verona Pharma Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 01, 2021: Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Feb 18, 2021: Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Nov 23, 2020: Verona Pharma secures up to \$30 million debt financing from Silicon Valley Bank

Oct 29, 2020: Verona Pharma operational update and financial results for the three and nine months ended September 30, 2020

Aug 14, 2020: Verona Pharma operational update and financial results for the three and six months ended June 30, 2020

Apr 08, 2020: Update on AGM Procedure

Feb 27, 2020: Verona Pharma reports financial results for the full year ended December 31, 2019 and Provides Corporate Update

Feb 03, 2020: Verona Pharma announces senior management changes

Jan 07, 2020: Verona Pharma appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Verona Pharma Plc, Key Facts
Verona Pharma Plc, Key Employees
Verona Pharma Plc, Key Employee Biographies
Verona Pharma Plc, Major Products and Services
Verona Pharma Plc, History
Verona Pharma Plc, Subsidiaries
Verona Pharma Plc, Key Competitors
Verona Pharma Plc, Ratios based on current share price
Verona Pharma Plc, Annual Ratios
Verona Pharma Plc, Annual Ratios (Cont...1)
Verona Pharma Plc, Interim Ratios
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Verona Pharma Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Verona Pharma Plc, Performance Chart (2016 - 2020)

Verona Pharma Plc, Ratio Charts

Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Verona Pharma Plc (VRNA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/V35B12B461FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V35B12B461FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970